← All trials
NCT05851508
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2023
- Primary completion
- May 1, 2026
- Completion date
- Feb 1, 2027
- First posted
- May 9, 2023
- Last posted
- Dec 4, 2023
- Enrollment
- 148
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Leiden UniversityLead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- Maastricht UniversityCollaborator
- Maastricht UniversityCollaborator
- Leiden UniversityReponsible party - principal investigator
- Medisch Spectrum TwenteCollaborator
- HagaZiekenhuisCollaborator
- Gelre HospitalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.